Incidence and treatment patterns of acute retinal necrosis: a nationwide population-based cohort study.
Masahiro Akada, Masayuki Hata, Yuki Muraoka, Kenji Ishihara, Shin Kadomoto, Hiroaki Ueshima, Hiroshi Tamura, Akitaka Tsujikawa, Masahiro Miyake, Yoshihiko Usui
Summary
In the largest population-based study of ARN to date, nationwide incidence in Japan closely matched prior UK estimates, suggesting cross-system consistency in ARN epidemiology.
Abstract
AIMS
To quantify nationwide incidence and contemporary treatment patterns of acute retinal necrosis (ARN).
METHODS
Retrospective cohort using Japan's National Database of Health Insurance Claims and Specific Health Checkups, which covers >95% of claims. New-onset ARN (2016-2022) was identified by ARN diagnostic codes plus antiviral therapy. Annual, age-specific and sex-specific incidence rates used governmental denominators; age-standardised rates used the WHO world standard. Surgical management (vitreoretinal surgery, silicone oil (SO)/perfluorocarbon (PFC) use, glaucoma surgery) was assessed up to 2 years after diagnosis.
RESULTS
Among 586 incident cases (313 men, 273 women), crude incidence was 0.066 (95% CI 0.061 to 0.072) per 100 000 person-years; the age-standardised rate was 0.040 per 100 000 person-years. Incidence rose with age, peaking at 70-74 years, and was consistently higher in men than in women. Vitreoretinal surgery occurred in 42.4% by 30 days and 59.4% by 365 days after diagnosis; 25.1% underwent ≥2 procedures within 1 year. SO or PFC was used in 40.8% by 1 year. Glaucoma surgery was uncommon (<2% by 2 years).
CONCLUSION
In the largest population-based study of ARN to date, nationwide incidence in Japan closely matched prior UK estimates, suggesting cross-system consistency in ARN epidemiology. Management was characterised by early, intensive surgery with frequent tamponade use and substantial reoperation, informing clinical triage and resource planning for this rare, vision-threatening condition.
Keywords
More by Masahiro Akada
View full profile →Sleep Disturbance as a Risk Factor for Retinal Neurodegeneration and Subsequent Glaucoma.
Risk of Glaucoma and Undergoing Glaucoma Surgery in Myopic and Highly Myopic Eyes: A Nationwide Population-Based Cohort Study.
Using artificial intelligence to improve human performance: efficient retinal disease detection training with synthetic images.
Top Research in Epidemiology & Genetics
Browse all →The Risks and Benefits of Myopia Control.
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Neuroprotective strategies for retinal disease.
Discussion
Comments and discussion will appear here in a future update.